Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid IntoxicationBusiness Wire • 09/26/22
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business ProgressBusiness Wire • 09/09/22
Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26Business Wire • 08/23/22
Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid IntoxicationBusiness Wire • 07/05/22
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022Business Wire • 06/23/22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific OfficerBusiness Wire • 05/24/22
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent UpdatesBusiness Wire • 05/11/22
Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND SubmissionBusiness Wire • 04/01/22
Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid IntoxicationBenzinga • 02/11/22
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent UpdatesBusiness Wire • 02/11/22
Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public RelationsBusiness Wire • 01/06/22
Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceBusiness Wire • 01/06/22
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and DirectorBusiness Wire • 01/04/22
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid IntoxicationBusiness Wire • 01/03/22
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business UpdateBusiness Wire • 11/12/21
Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid OverdoseBusiness Wire • 10/13/21
Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose ProblemBenzinga • 10/12/21
CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical TrialsBenzinga • 09/23/21
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business UpdateBusiness Wire • 09/22/21
Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical TrialBusiness Wire • 09/13/21
Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/07/21